RYTM Rhythm Pharmaceuticals, Inc. | US76243J1051
Financials
Trends
Details
| Breakdown | 31.12.2027 | 31.12.2026 | Change % |
|---|---|---|---|
| Total Revenue | 538.995.330 | 297.832.060 | 80.97% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| Operating Expense | -- | -- | -- |
| Selling General and Administrative | -- | -- | -- |
| Research & Development | -- | -- | -- |
| Operating Income | -- | -- | -- |
| Pretax Income | -- | -- | -- |
| Net Income Common Stockholders | -- | -- | -- |
| Basic EPS | -0,74 | -3,29 | 77.57% |
| Diluted EPS | -- | -- | -- |
| Analyst Count | 9 | 10 | 10.00% |
| EBIT | -- | -- | -- |
| EBITDA | -- | -- | -- |